Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas

13 September 2010

Switzerland-based Basilea (BSLN: S) says that its partner Janssen-Cilag AG, a unit of US health care giant Johnson & Johnson (NYSE: JNJ) ill be discontinuing the sale of Zevetera (ceftobiprole) in Switzerland as of September 17, 2010, for the treatment of complicated skin and soft tissue infections.

This action was based on the recent unfavorable assessments of the applications for ceftobiprole in the USA and Europe (The Pharma Letter February 22). Janssen-Cilag said that it has submitted a market authorization withdrawal request to Swissmedic for Zevetera, and also said that it will be making similar requests to Health authorities in Russia, Ukraine and Azerbaijan requesting them to withdraw the Marketing Authorizations for the drug.

Progresses antifungal development

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK